SCHEMBL1347958

SCHEMBL1347958

C(=CC1CCNCC1)c1cncnc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KHK P50053 1/20 0.36
CHRNB2 P17787 1/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA4 P43681 1/20 0.35
HRH3 Q9Y5N1 6/20 0.34
ROCK2 O75116 3/20 0.32
ROCK1 Q13464 3/20 0.32
CHUK O15111 1/20 0.32
DYRK3 O43781 1/20 0.32
MAP4K4 O95819 1/20 0.32
PIM1 P11309 1/20 0.32
PRKACA P17612 1/20 0.32
RPS6KB1 P23443 1/20 0.32
AKT1 P31749 1/20 0.32
CLK2 P49760 1/20 0.32
PRKX P51817 1/20 0.32
PRKG2 Q13237 1/20 0.32
DYRK1A Q13627 1/20 0.32
PRKG1 Q13976 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1347957 1.00 KHK (0.36) KHKCHRNB2CHRNB4CHRNA3CHRNA4
Simpinicline SCHEMBL250743 0.89 CHRNB2 (0.40) KHKCHRNB2CHRNB4CHRNA3CHRNA4
Simpinicline SCHEMBL1333778 0.89 CHRNB2 (0.40) KHKCHRNB2CHRNB4CHRNA3CHRNA4
Simpinicline SCHEMBL1335091 0.89 CHRNB2 (0.40) KHKCHRNB2CHRNB4CHRNA3CHRNA4
Simpinicline SCHEMBL250744 0.89 CHRNB2 (0.40) KHKCHRNB2CHRNB4CHRNA3CHRNA4
Simpinicline SCHEMBL1333776 0.89 CHRNB2 (0.40) KHKCHRNB2CHRNB4CHRNA3CHRNA4
Simpinicline SCHEMBL1335095 0.89 CHRNB2 (0.40) KHKCHRNB2CHRNB4CHRNA3CHRNA4
Simpinicline SCHEMBL19436720 0.89 CHRNB2 (0.40) KHKCHRNB2CHRNB4CHRNA3CHRNA4
Simpinicline SCHEMBL23699062 0.88 CHRNB2 (0.39) KHKCHRNB2CHRNB4CHRNA3CHRNA4
Simpinicline SCHEMBL23699063 0.88 CHRNB2 (0.39) KHKCHRNB2CHRNB4CHRNA3CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008157365-A2 VINYLAZACYCLOALKANES FOR TREATING NEUROPATHIC PAIN TARGACEPT, INC. (US) 2008-12-24 WO claimed
EP-1601670-B1 ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF TARGACEPT INC (US) 2008-05-07 EP claimed
US-7098331-B2 Arylvinylazacycloalkane compounds and methods of preparation and use thereof TARGACEPT, INC. (US) 2006-08-29 US claimed
US-20040176348-A1 Arylvinylazacycloalkane compounds and methods of preparation and use thereof AVENTIS PHARMA S.A. 2004-09-09 US claimed
US-20150164894-A1 ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF TARGACEPT, INC. 2015-06-18 US disclosed
US-20140107164-A1 ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF TARGACEPT, INC. (US) 2014-04-17 US disclosed
US-8633222-B2 Arylvinylazacycloalkane compounds and methods of preparation and use thereof TARGACEPT, INC. (US) 2014-01-21 US disclosed
US-8067443-B2 Arylvinylazacycloalkane compounds and methods of preparation and use thereof TARGACEPT, INC. (US) 2011-11-29 US disclosed
US-8063068-B2 Arylvinylazacycloalkane compounds and methods of preparation and use thereof TARGACEPT, INC. (US) 2011-11-22 US disclosed
US-20110152293-A1 ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF TARGACEPT, INC. (US) 2011-06-23 US disclosed
US-20100267776-A1 ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF TARGACEPT, INC. (US) 2010-10-21 US disclosed
US-7714001-B2 Arylvinylazacycloalkane compounds and methods of preparation and use thereof TARGACEPT, INC. (US) 2010-05-11 US disclosed
WO-2008157365-A2 VINYLAZACYCLOALKANES FOR TREATING NEUROPATHIC PAIN TARGACEPT, INC. (US) 2008-12-24 WO disclosed
US-20080293778-A1 Arylvinylazacycloalkane Compounds and Methods of Preparation and Use Thereof TARGACEPT, INC. (US) 2008-11-27 US disclosed
EP-1947100-A1 Arylvinylazacycloalkane compounds and methods of preparation and use thereof Targacept, Inc. (US) 2008-07-23 EP disclosed
EP-1601670-B1 ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF TARGACEPT INC (US) 2008-05-07 EP disclosed
US-7098331-B2 Arylvinylazacycloalkane compounds and methods of preparation and use thereof TARGACEPT, INC. (US) 2006-08-29 US disclosed
EP-1601670-A1 ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF Targacept Inc. (US) 2005-12-07 EP disclosed
WO-2004078752-A1 ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF TARGACEPT INC. (US) 2004-09-16 WO disclosed
US-20040176348-A1 Arylvinylazacycloalkane compounds and methods of preparation and use thereof AVENTIS PHARMA S.A. 2004-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176348-A1 Arylvinylazacycloalkane compounds and methods of preparation and use thereof CHRNA5, OPRK1, CHRNA6 KHK 1070/4885CHRNB2 7/4885CHRNB4 15/4885
US-20110152293-A1 ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF CHRNA5, OPRK1, CHRNA6 KHK 1070/4885CHRNB2 7/4885CHRNB4 15/4885
US-20140107164-A1 ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF CHRNA5, OPRK1, CHRNA6 KHK 1070/4885CHRNB2 7/4885CHRNB4 15/4885
US-20080293778-A1 Arylvinylazacycloalkane Compounds and Methods of Preparation and Use Thereof CHRNA5, OPRK1, CHRNA6 KHK 1070/4885CHRNB2 7/4885CHRNB4 15/4885
US-20150164894-A1 ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF CHRNA5, OPRK1, CHRNA6 KHK 1070/4885CHRNB2 7/4885CHRNB4 15/4885
US-20100267776-A1 ARYLVINYLAZACYCLOALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF CHRNA5, OPRK1, CHRNA6 KHK 1070/4885CHRNB2 7/4885CHRNB4 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.